Table 2.
Gender and age for SGLT-2i use
| Gender | Age | ||||||
|---|---|---|---|---|---|---|---|
| Male (n, %) | Female (n, %) | Unknown (n, %) | < 18 (n) | 18–65 (n) | > 65 (n) | Average (years) | |
| Canagliflozin | 222 (25.87%) | 538 (62.70%) | 98 (11.42%) | 0 | 292 | 131 | 59 |
| Canagliflozin/metformin | 2 (8.70%) | 18 (78.26%) | 3 (13.04%) | 0 | 11 | 2 | 56 |
| Dapagliflozin | 95 (29.23%) | 198 (60.92%) | 32 (9.85%) | 0 | 125 | 62 | 60 |
| Dapagliflozin/metformin | 9 (37.50%) | 15 (62.50%) | 0 (0.00%) | 0 | 7 | 7 | 62 |
| Dapagliflozin/saxagliptin | 0 (–) | 0 (–) | 0 (–) | 0 | 0 | 0 | – |
| Empagliflozin | 68 (35.98%) | 109 (57.67%) | 12 (6.35%) | 0 | 71 | 56 | 63 |
| Empagliflozin/linagliptin | 4 (17.39%) | 17 (73.91%) | 2 (8.70%) | 0 | 8 | 4 | 64 |
| Empagliflozin/metformin | 62 (33.88%) | 109 (59.56%) | 12 (6.56%) | 0 | 69 | 51 | 62 |
| Ertugliflozin | 2 (66.67%) | 1 (33.33%) | 0 (0.00%) | 0 | 1 | 0 | 46 |
| Ertugliflozin/metformin | 0 (–) | 0 (–) | 0 (–) | 0 | 0 | 0 | – |
| Ertugliflozin/sitagliptin | 0 (–) | 0 (–) | 0 (–) | 0 | 0 | 0 | – |
| Ipragliflozin | 0 (–) | 0 (–) | 0 (–) | 0 | 0 | 0 | – |
| Luseogliflozin | 0 (–) | 0 (–) | 0 (–) | 0 | 0 | 0 | – |
| Tofogliflozin | 0 (–) | 0 (–) | 0 (–) | 0 | 0 | 0 | – |